• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

Whitepaper: High-throughput phenotypic screening with Organ-on-a-chip: a perfused 3D microfluidic angiogenesis assay

Cells in vivo experience a complex, three-dimensional environment that exposes them to circulating molecules, neighboring cells, and the extracellular matrix (ECM). Organ-on-a-Chip is a powerful technology driving human relevance by utilizing microfluidic techniques. Organ-on-a-Chip systems, such as the MIMETAS OrganoPlate® platform, aim to mimic cell-matrix and cell-cell interactions, and recreates human tissue microenvironment in vitro.

Since most platform technologies are either based on single chips or small numbers of chips in dedicated surroundings, applications for Organ-on-a-chip are largely envisioned in pre-clinical testing. MIMETAS’ platform combines physiological relevance with scalability to enable the potential of automation, facilitating upscaling and streamlining research processes.

In this white paper, we give a detailed report on a 1546 compound screen on a robust 3D angiogenic sprouting assay. Download the white paper to learn exactly how we combined the OrganoPlate® platform with an automated workflow to deploy it as a high-throughput screening tool. You will also explore how image-based phenotypic screening offers high-resolution information and generates selective hits and novel biological insights.

Download the whitepaper here


May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all